Necroptosis
Necroptosis is a form of programmed cell death that is morphologically similar to necrosis but is regulated by specific signaling pathways. Unlike apoptosis, which is a form of programmed cell death that occurs in a controlled and non-inflammatory manner, necroptosis results in cell lysis and the release of cellular contents, leading to inflammation.
Mechanism[edit | edit source]
Necroptosis is primarily mediated by the receptor-interacting protein kinases RIPK1 and RIPK3. Upon activation by various stimuli, such as tumor necrosis factor (TNF), these kinases form a complex known as the necrosome. The necrosome then phosphorylates and activates the pseudokinase MLKL (mixed lineage kinase domain-like protein), which translocates to the plasma membrane and disrupts its integrity, leading to cell death.
Key Proteins Involved[edit | edit source]
- RIPK1: Receptor-interacting serine/threonine-protein kinase 1
- RIPK3: Receptor-interacting serine/threonine-protein kinase 3
- MLKL: Mixed lineage kinase domain-like protein
Biological Significance[edit | edit source]
Necroptosis plays a crucial role in various physiological and pathological processes. It serves as a defense mechanism against certain pathogens that inhibit apoptosis. Additionally, necroptosis is involved in inflammatory diseases, neurodegenerative diseases, and ischemia-reperfusion injury.
Pathological Implications[edit | edit source]
Dysregulation of necroptosis has been implicated in several diseases:
- Inflammatory diseases: Excessive necroptosis can contribute to chronic inflammation and tissue damage.
- Neurodegenerative diseases: Abnormal activation of necroptosis pathways has been observed in conditions such as Alzheimer's disease and Parkinson's disease.
- Ischemia-reperfusion injury: Necroptosis contributes to cell death and tissue damage following the restoration of blood supply after a period of ischemia.
Research and Therapeutic Potential[edit | edit source]
Understanding the molecular mechanisms of necroptosis has opened new avenues for therapeutic interventions. Inhibitors targeting key components of the necroptosis pathway, such as RIPK1 and RIPK3, are being explored for their potential to treat inflammatory and neurodegenerative diseases.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD